

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2013**

(Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Half Year Ended on		Year Ended on
		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
		Unaudited	Unaudited	Unaudited			Audited
1	Net Sales/ Income from operations						
	Gross Sales	1246.96	1268.79	1106.83	2515.75	2,230.38	4,602.58
	Less : Excise Duty	1.68	2.34	2.52	4.02	5.93	11.61
	(a) Net Sales	1245.28	1266.45	1104.11	2511.73	2224.45	4,590.97
	(b) Other Operating Income	7.15	5.63	4.02	12.78	9.40	22.41
	Total Income from Operation (Net)	1,252.43	1,272.08	1,108.13	2,524.51	2,233.85	4,613.38
2	Expenses						
	(a) Consumption of raw materials	704.12	752.50	652.18	1456.62	1,304.55	2,725.58
	(b) (Increase)/ Decrease in stock in trade	22.51	(2.80)	(31.9)	19.71	(61.65)	(92.93)
	(c) Employee benefits expense	59.66	59.17	58.06	118.83	115.16	232.38
	(d) Depreciation & amortisation expense	96.87	95.35	79.77	192.22	157.46	317.62
	(e) Other expenses	142.15	147.14	141.90	289.29	290.70	563.47
	Total expense	1,025.31	1,051.36	900.01	2,076.67	1,806.22	3,746.12
3	Profit from operations before other income , finance costs and exceptional items (1-2)	227.12	220.72	208.12	447.84	427.63	867.26
4	Other income	0.21	8.18	2.69	8.39	3.95	3.95
5	Profit before finance costs and exceptional items (3+4)	227.33	228.90	210.81	456.23	431.58	871.21
6	Finance Costs	69.21	66.81	53.72	136.02	129.87	244.49
7	Profit after finance costs but before exceptional items (5-6)	158.12	162.09	157.09	320.21	301.71	626.72
8	Exceptional items	---	---	---	---	---	---
9	Profit from ordinary activities before tax (7+8)	158.12	162.09	157.09	320.21	301.71	626.72
10	Tax expense	8.15	8.97	6.17	17.12	10.34	55.27
11	Profit from ordinary activities after tax (9-10)	149.97	153.12	150.92	303.09	291.37	571.45
12	Exceptional items (net of tax expense)	---	---	---	---	---	---
13	Net profit for the period (11-12)	149.97	153.12	150.92	303.09	291.37	571.45
14	Paid up Equity Share Capital	114.42	114.42	97.42	114.42	97.42	105.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	N. A.	N. A.	3,769.22
16	E.P.S - Basic not annualised for the qtr	13.11	13.38	15.49	26.49	29.91	54.21
	- Annualised	52.43	53.53	61.97	52.98	59.82	54.21
	Part - II						
1	Public Shareholding						
	- Number of Shares	6437086	6437086	6437086	6437086	6437086	6437086
	- Percentage of Shareholding	56.26	56.26	66.08	56.26	66.08	61.06
2	Promoters and promoter group shareholding						
	a) Pledged as collateral security to bank						
	- Number of Shares	1930000	1930000	1881900	1930000	1881900	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	38.56	38.56	56.94	38.56	56.94	47.02
	- Percentage of shares (as a % of the total share capital)	16.87	16.87	19.31	16.87	19.31	18.31
	b) Non-Encumbered						
	- Number of Shares	3074902	3074902	1423002	3074902	1423002	2174902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	61.44	61.44	43.06	61.44	43.06	52.98
	- Percentage of shares (as a % of the total share capital)	26.87	26.87	14.61	26.87	14.61	20.63
	Particulars	3 months ended 30.09.2013					
	(B) INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	1					
	Disposed of during the quarter	1					
	Remaining unresolved at the end of the quarter	NIL					



Notes:

1. The above Un-audited (Provisional) financial Results for the period ended 30.09.2013 were reviewed by the Audit Committee and taken on record at the board Meeting on November 11, 2013.
2. During the Quarter:
 - The company has been granted patent from the Japanese Patent Office for Eiores.
 - The Company has got all the facilities approved for GMP Ukrain, a PIC/s nation. Venus is the only Company who is having a Ukrainian GNP approval for large Volume Parenteral for its Panchkula facility India.
 - Company's R&D Centre, Venus Medicine Research Centre (VMRC) has been accredited for Good Laboratory Practices (GLP) and norms on Organization for Economic Co-operation and Development (OECD) Principles by National GLP and Compliance Monitoring Authority (NGCMA).
 - Venus Pharma GmbH, a subsidiary of Venus Remedies Limited has made big strides in the global market by bagging marketing authorisation approval from France for Meropenem, a generic broad spectrum antibiotic injectable. It has signed a non- exclusive marketing rights deal with generic giant Mylan to sell Meropenem in France, world's 5th largest pharmaceutical market.
3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.
4. During the Quarter, one investor grievance was received and resolved. No other investor grievance was pending at the end of the quarter.
5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

A handwritten signature in green ink, appearing to read "Pawan Chaudhary", is written over the printed name.

(Pawan Chaudhary)
Chairman & Managing Director

Place : Panchkula
Date : 11.11.2013

Standalone Statement of Assets and Liabilities

Clause 41 of the Listing Agreement For Companies (Other than Banks)

PARTICULARS		Year Ended on 30/09/2013 (Rs. In Millions)	Year Ended on 31/03/2013 (Rs. In Millions)
A	EQUITY AND LIABILITIES		
1.00	Shareholders' funds		
	(a) Share capital	114.42	105.42
	(b) Reserves and surplus	4254.30	3769.22
	(c) Money received against share warrants	0.00	47.74
	Sub-total – Shareholders' funds	4368.72	3922.38
2.00	Non-current liabilities		
	(a) Long-term borrowings	1500.52	1291.15
	(b) Deferred tax liabilities (net)	146.81	146.81
	(c) Other long-term liabilities	5.79	4.66
	(d) Long-term provisions	33.75	29.14
	Sub-total – Non-current liabilities	1686.87	1471.76
3.00	Current liabilities		
	(a) Short-term borrowings	1003.85	956.81
	(b) Trade payables	246.37	178.70
	(c) Other current liabilities	373.30	578.83
	(d) Short-term provisions	81.38	186.29
	Sub-total – Current liabilities	1704.90	1900.63
	TOTAL – EQUITY AND LIABILITIES	7760.49	7294.77
B	ASSETS		
1.00	Non-current assets		
	(a) Fixed assets	4590.80	4287.25
	(b) Non-current investments	287.36	287.36
	(c) Long-term loans and advances	478.98	427.40
	Sub-total – Non-current assets	5357.14	5002.01
2.00	Current assets		
	(a) Current investments		
	(b) Inventories	1342.45	1263.97
	(c) Trade receivables	518.47	531.13
	(d) Cash and cash equivalents	43.67	62.59
	(e) Short-term loans and advances	498.76	435.07
	Sub-total – Current assets	2403.35	2292.76
	TOTAL – ASSETS	7760.49	7294.77